CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform

Peak revenue. This figure is an explicitly hypothetical cohort-consistency illustration, not a product forecast — the asset has no lead clinical candidate, no defined single indication, and no delivery vehicle, so a 'pan-cancer platform peak' would be a category error. As a partnership/licensed-platform, Johns Hopkins would realize value as milestones plus a 5–15% royalty on a future licensee's product, not full product peak. The $600M figure conservatively models the royalty/milestone-equivalent NPV anchor IF a single biomarker-defined pancreatic-cancer program were eventually partnered, deliberately set below the lonvo-z-class single-indication in vivo CRISPR opportunity to reflect that delivery to disseminated PDAC is unproven and the value here is licensing, not commercialization.

WACC. A preclinical oncology platform whose entire thesis hinges on an unsolved in vivo delivery problem and which has no lead candidate sits at the high end of biotech discount rates, above standard gene-therapy risk (12–14%) and consistent with partnership-stage, delivery-unproven platform technology.

This is a genuine therapeutic concept but at a very early platform stage, not a fundable product. The Eshleman lab at Johns Hopkins exploits a real biological insight: tumor-specific somatic point mutations create novel protospacer-adjacent motifs (PAMs) that exist only in cancer cells, so Cas9 directed by tumor-specific guide RNAs makes lethal multiplexed double-strand breaks in malignant cells while sparing PAM-absent normal tissue (Cas9 "neither binds nor cuts the target in its absence"). The peer-reviewed data are in vitro: ~417 somatic PAMs per pancreatic tumor and 69–99% selective killing with 4–9 sgRNAs, with DNA-repair-inhibitor synergy. Critically, the same paper states no in vivo systemic delivery has been demonstrated — this is a guide-RNA-design and IP platform with mouse work in progress, not a clinical candidate, and the rNPV envelope below is shown for cohort consistency only; the value path is licensing the platform to a delivery-capable developer, which is why it is classified partnership_candidate, not vc_fundable.

The comparators frame why. Intellia's lonvo-z proves an in vivo Cas9-plus-guide-RNA medicine can reach Phase 3 and an FDA BLA — but only by knocking out one gene in the liver, the organ lipid nanoparticles naturally home to; disseminated pancreatic adenocarcinoma (13.7% five-year survival, 51% metastatic at diagnosis) is the hardest delivery target in oncology. Excision's EBT-101 is the cautionary mirror: an in vivo multiplexed CRISPR that was safely delivered yet failed to prevent HIV rebound because editing penetrance was insufficient — and this asset must achieve lethal editing in essentially every cell of a stroma-dense tumor using more guides. The engine result is -$55.3M to -$29.8M, with a base rNPV of -$42.5M and cumulative PoS of 1.1%; that wide, low spread is the correct read for a delivery-unsolved preclinical platform whose economic value, if realized, accrues as milestones and a 5–15% royalty to Johns Hopkins rather than as a standalone product peak.

Verdict: a scientifically credible, mechanistically elegant cancer-killing concept whose entire investment case rests on an unsolved in vivo delivery problem and which has no lead candidate or single indication. It earns its rank-15 slot on the rubric's modality_pos (gene-therapy bucket), high IRA exposure for a biologic, and clinical-relevance signal in a severe-unmet-need cancer — not on being a fundable product. The honest archetype is partnership_candidate: the right next step is licensing the guide-design IP to a group that has solved targeted CRISPR delivery to solid tumors, because that capability — not the cutting concept — is the binding constraint.